Medisi America
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES

Finding a non-invasive way to predict effectiveness of cancer therapy.

By Medisi America on 30 diciembre, 2019

«Researchers have taken a critical step toward developing a non-invasive nuclear medicine technique that can predict the effectiveness of therapy for cancerous tumors, allowing for personalized, precision treatment.»

Read more.

 

Posted in News.
Share
←  NewerResMed ventilators recall is Class I
Older  →Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices

Entradas recientes

  • COFEPRIS Evolves
  • COFEPRIS Challenges 2020
  • ResMed ventilators recall is Class I
  • Finding a non-invasive way to predict effectiveness of cancer therapy.

NEWS

  • Conferences
  • News
  • Science
  • Technology

Deja una respuesta Cancelar la respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Related Posts

  • 19 febrero, 2020

    ResMed ventilators recall is Class I

    FDA today designated a ResMed (NYSE:RMD) recall of certain Stellar non-invasive and invasive ventilators as Class I — the agency’s most serious level. The sound alarm on the ventilators may not work if the device has a failed electronic part, is stored without AC power for more than 36 hours, or powers on automatically when connected …

  • 18 junio, 2019

    Stroke significantly increases the risk of dementia

    In the largest study of its kind, researchers conclude that stroke doubles the risk that an individual will eventually develop dementia. If you want to read more about this news click here.

  • 18 junio, 2019

    Using EEG data to diagnose Parkinson’s disease

    Researchers behind a new study believe that an EEG may be a more effective alternative. If you want to read more about this news click here  

  • 10 octubre, 2019

    Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

    Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study. The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total …

  • © 2026 MEDISI America - All rights reserved
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES